Amikacin点滴静注法による基礎的研究ならびに尿路感染症に対する臨床的効果

Abstract

Absorption, excretion and clinical studies of amikacin by intravenous drip infusion were investigated and following results were obtained. 1) Serum concentrations and urinary excretions of amikacin after a single intravenous drip infusion of 100 mg or 200 mg over an hour were determined in 6 healthy male volunteers. Peak serum concentration was noted just after the end of infusion at the level of7.50 to 8.61 µg/ml, averagely 8.07 µg/ml, in the 100 mg administered group and 13.9 to 18.8 µg/mI, averagely 16.07 µg/ml, in the 200 mg administered group, thereafter the concentration relatively rapidly decreased. Clear dose response was found between two groups. Urinary excretion was 60.65 to 69.80%, averagely 64.36%, in the 100 mg administered group and 60.71 to 81.55%, averagely 68.78%, in the 200 mg administered group up to 6 hours after the end of infusion. No significant difference was observed between two groups. 2) Amikacin was clinically administered to 7 patients with pyelonephritis and 4 with epididymitis (5 with complicated urinary tract infection, 6 with simple urinary tract infection) by intravenous drip infusion. 81.8% of the patients showed favorable response to the amikacin therapy. 3) No side effect was observed in this series.